Abstract
The pharmaceutical industry is testing new potential drugs for their propensity to prolong human cardiac repolarization, and regards this as a sign of proarrhythmic risk. Many studies have dethroned the common perception that prolonged repolarization is a reliable surrogate marker for torsades de pointes (TdP) arrhythmia. Both the pharmaceutical industry and the regulatory bodies are neglecting the available proarrhythmia models. In vitro studies have suggested that combined pharmacological hits on repolarization will produce a superior substrate for in vivo proarrhythmia, compared to the single-drug assessment. By using consecutive pharmacological challenges, a simple model is proposed, in which combinatorial pharmacology is employed to provoke TdP in the conscious dog. The pharmaceutical industry interested in evaluating the proarrhythmic potential of their present and future drugs now has a simple means of doing so.
| Original language | English |
|---|---|
| Journal | British Journal of Pharmacology |
| Volume | 151 |
| Issue number | 7 |
| Pages (from-to) | 909-11 |
| Number of pages | 3 |
| ISSN | 0007-1188 |
| DOIs | |
| Publication status | Published - Aug 2007 |
Keywords
- Animals
- Chromans
- Delayed Rectifier Potassium Channels
- Dogs
- Drug Synergism
- Drug Toxicity
- Electrocardiography
- Humans
- Long QT Syndrome
- Phenethylamines
- Potassium Channel Blockers
- Potassium Channels, Voltage-Gated
- Rabbits
- Risk Factors
- Sulfonamides
- Torsades de Pointes